
The proprietary platform of 19 Fluid
1. Detect fluid/solution dynamic conformation of full length GPCRs
-
- Proprietary purification of native, full-length GPCR
- Protein NMR with proprietary 19 F labeling scheme to capture coupling of scaffold proteins (G-protein, beta-arrestin) to GPCR
2. Empowers drug discovery beyond current state of the art
3. Platform is agnostic to therapeutic area
4. Successfully applied to multiple targets
-
- MOR, DOR
- S1PR1
- b1AR, b2AR
- Additional GPCRs have been expressed and purified as potential targets (e.g., MLNR, A2A)
Uncovering extremely ‘biased’ mor agonists
